Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG0103 in chronic discogenic lumbar back pain
NCT03263611Phase 1Completed
- Sponsor
- AnGes, Inc.
- Start
- Feb 2018
- Primary completion
- Feb 2021
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cupabimod in degenerative disc disease (DDD) (4 arms), sponsored by AnGes, Inc. Primary endpoints: Treatment-emergent adverse events (AEs) at 6 months, Data from 12-lead electrocardiograms at 6 months and 1 more. Started Feb 2018; status: completed.
02
Drugs
cupabimod
03
Conditions
degenerative disc disease (DDD)
Beyond the preview
Go deeper on NCT03263611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03263611.